HemaCare and Charles River Laboratories Announce Strategic Partnership to Accelerate Drug Discovery and Development
PBMC humanization kits for NCG mouse models facilitate infectious disease and immuno-oncology research
(Los Angeles, CA – February 6, 2018) HemaCare Corporation (OTCBB: HEMA), a global leader in the customization of human-derived biological products and services for biomedical research and cell therapy, and Charles River Laboratories International, Inc., a leading early-stage contract research organization, have formed a strategic partnership to advance human immune system research by developing a more efficient and reliable method of working with humanized mice.
Under the partnership, HemaCare’s peripheral blood mononuclear cells (PBMCs) will be integrated into Charles River’s NCG/PBMC Select Humanization Kit. This kit is the first of its kind in the industry and provides both the NCG mouse and vials of pre-selected human PBMCs, allowing the researcher to efficiently develop the humanized mouse model.
The key to the creation of humanized mice is the engraftment of human PBMCs, which allows for development of human immune systems. The challenges that researchers often face is that engraftment varies with each PBMC donor. By evaluating human PBMCs from donors in advance, optimal donors can be identified, pre-qualified, and their cells included in the humanized mouse model kit.
“In drug discovery and development, humanized mouse models have emerged as an essential tool in researching novel therapies for patients,” said Iva Morse, Corporate Vice President, Chief Scientific Officer, Global RMS at Charles River. “We’ve formed a strategic alliance with HemaCare because they have one of the largest donor databases in the world, an FDA-approved collection center, and the ability to pre-screen and qualify the donors.”
Delivering the highest-quality human cells and animal models to researchers is a top priority for HemaCare and Charles River. By providing customers with this humanized mouse kit, potentially weeks of additional work needed to qualify PBMC donor cells can be avoided.
“HemaCare continues to develop strategic partnerships to expand the breadth and depth of our product portfolio,” said Lou Juliano, HemaCare’s SVP of Global Sales and Business Development. “Charles River and HemaCare are both deeply committed and laser-focused on helping researchers with their mouse humanization needs. Optimized human mouse models can accelerate drug discovery and ultimately improve patient outcomes.”
Available immediately from Charles River, the standard NCG/PBMC Select Humanization Kit configuration includes ten NCG mouse models and a sufficient number of pre-selected PBMCs for engraftment. More information about the kit is available here: https://www.criver.com/about-us/ncgpbmc-select-humanization-kit
HemaCare is a global leader in the customization of human-derived biological products and services for biomedical research, drug discovery and cellular therapy process development. The company’s network of FDA-registered, GMP/GTP-compliant collection centers ensure fresh donor material is available to customers and for use within HemaCare’s isolation laboratory. Human biological material including peripheral blood, bone marrow, and cord blood is isolated into various primary cells types for fresh and frozen distribution. For 40 years, HemaCare has developed an extensive registry of repeat donors and provides human-derived primary blood cells and tissues for biomedical and drug discovery research and cell therapy clinical trials, and supports commercialization with apheresis collections, directly enabling customers to advance both autologous and allogeneic cellular therapies.
For more information, please visit www.hemacare.com.
Business Development Contact: